Uneingeschränkter Zugang

The protective action of piperlongumine against mycobacterial pulmonary tuberculosis in its mitigation of inflammation and macrophage infiltration in male BALB/c mice

Nihong Lu

Nihong Lu

Department of Respiratory and Critical Care, The Third People’s Hospital of KunmingKunming, China
Suche nach diesem Autor auf
Sciendo|Google Scholar
Lu, Nihong
, 
Yongrui Yang

Yongrui Yang

Department of Respiratory and Critical Care, The Third People’s Hospital of KunmingKunming, China
Suche nach diesem Autor auf
Sciendo|Google Scholar
Yang, Yongrui
, 
Xiaofei Li

Xiaofei Li

Department of Respiratory and Critical Care, The Third People’s Hospital of KunmingKunming, China
Suche nach diesem Autor auf
Sciendo|Google Scholar
Li, Xiaofei
, 
Jie Li

Jie Li

Department of Respiratory and Critical Care, The Third People’s Hospital of KunmingKunming, China
Suche nach diesem Autor auf
Sciendo|Google Scholar
Li, Jie
, 
Jie Cheng

Jie Cheng

Department of Respiratory and Critical Care, The Third People’s Hospital of KunmingKunming, China
Suche nach diesem Autor auf
Sciendo|Google Scholar
Cheng, Jie
, 
Zhengxuan Lv

Zhengxuan Lv

Department of Respiratory and Critical Care, The Third People’s Hospital of KunmingKunming, China
Suche nach diesem Autor auf
Sciendo|Google Scholar
Lv, Zhengxuan
 und 
Yingrong Du

Yingrong Du

Department of Respiratory and Critical Care, The Third People’s Hospital of KunmingKunming, China
Suche nach diesem Autor auf
Sciendo|Google Scholar
Du, Yingrong
  
20. Nov. 2021
The protective action of piperlongumine against mycobacterial pulmonary tuberculosis in its mitigation of inflammation and macrophage infiltration in male BALB/c mice's Cover Image
Über diesen Artikel
Vorheriger Artikel
Nächster Artikel
Zitieren
COVER HERUNTERLADEN
Artikel-Kategorie: Review article
Online veröffentlicht: 20. Nov. 2021
Seitenbereich: 431 - 440
Eingereicht: 02. Apr. 2021
Akzeptiert: 26. Okt. 2021
DOI: https://doi.org/10.2478/jvetres-2021-0061
Schlüsselwörter
© 2021 N. Lu et al. published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Fig. 1

Effect of piperlongumine (PL) on cell viability in MH-S (6 × 105) cells cultured for 48 h with and without PL (2.5–45 μg/mL). Dimethyl sulphoxide (DMSO) was used as internal reference for comparison. Data are expressed as mean ± SD and show no significant differences between DMSO and PL treated cells
Effect of piperlongumine (PL) on cell viability in MH-S (6 × 105) cells cultured for 48 h with and without PL (2.5–45 μg/mL). Dimethyl sulphoxide (DMSO) was used as internal reference for comparison. Data are expressed as mean ± SD and show no significant differences between DMSO and PL treated cells

Fig. 2a

In vitro effects of piperlongumine (PL) on the inhibition production of TNF-α and IL-6 in trehalose 6,6-dimycolate (TDM)-activated MH-S cells. Data are expressed as mean ± SD of three experiments. DMSO – dimethyl sulphoxide; P1 –PL at 5 μg/mL; P2 – PL at 15 μg/mL; P3 – PL at 25 μg/mL; DEX – dexamethasone; ns – non-significant, P > 0.05; * P < 0.05; ** P < 0.01; *** P < 0.001 vs TDM-treated group
In vitro effects of piperlongumine (PL) on the inhibition production of TNF-α and IL-6 in trehalose 6,6-dimycolate (TDM)-activated MH-S cells. Data are expressed as mean ± SD of three experiments. DMSO – dimethyl sulphoxide; P1 –PL at 5 μg/mL; P2 – PL at 15 μg/mL; P3 – PL at 25 μg/mL; DEX – dexamethasone; ns – non-significant, P > 0.05; * P < 0.05; ** P < 0.01; *** P < 0.001 vs TDM-treated group

Fig. 2b

In vitro effects of piperlongumine (PL) on the inhibition of production of C-C motif chemokine ligand 2 (CCL-2), C-C motif chemokine ligand 10 (CXCL-10), C-C motif chemokine ligand 5 (CCL-5) and keratinocyte-derived chemokine (KC) in trehalose 6,6-dimycolate (TDM)-activated MH-S cells. Data are expressed as mean ± SD of three experiments. DMSO – dimethyl sulphoxide; P1 – PL 5 μg/mL; P2 – PL 15 μg/mL; P3 – PL 25 μg/mL; DEX – dexamethasone; ns – non-significant, P > 0.05; * P < 0.05; ** P < 0.01; *** P < 0.001 vs TDM-treated group
In vitro effects of piperlongumine (PL) on the inhibition of production of C-C motif chemokine ligand 2 (CCL-2), C-C motif chemokine ligand 10 (CXCL-10), C-C motif chemokine ligand 5 (CCL-5) and keratinocyte-derived chemokine (KC) in trehalose 6,6-dimycolate (TDM)-activated MH-S cells. Data are expressed as mean ± SD of three experiments. DMSO – dimethyl sulphoxide; P1 – PL 5 μg/mL; P2 – PL 15 μg/mL; P3 – PL 25 μg/mL; DEX – dexamethasone; ns – non-significant, P > 0.05; * P < 0.05; ** P < 0.01; *** P < 0.001 vs TDM-treated group

Fig. 3

Enhancing effect of piperlongumine (PL) on the clearance of mycobacterium from alveolar macrophages. Data are expressed as mean ± SD of three experiments. TDM – trehalose-6,6-dimycolate; DMSO – dimethyl sulphoxide; P1 – PL at 5 μg/mL; P2 – PL at 15 μg/mL; P3 – PL at 25 μg/mL; DEX – dexamethasone; ns – non-significant, P > 0.05; ** P < 0.01; *** P < 0.001 vs M. tuberculosis H37Rv strain infection group
Enhancing effect of piperlongumine (PL) on the clearance of mycobacterium from alveolar macrophages. Data are expressed as mean ± SD of three experiments. TDM – trehalose-6,6-dimycolate; DMSO – dimethyl sulphoxide; P1 – PL at 5 μg/mL; P2 – PL at 15 μg/mL; P3 – PL at 25 μg/mL; DEX – dexamethasone; ns – non-significant, P > 0.05; ** P < 0.01; *** P < 0.001 vs M. tuberculosis H37Rv strain infection group

Fig. 5

Diminution by piperlongumine of trehalose 6,6-dimycolate (TDM)-stimulated pulmonary granulomatous inflammation in BALB/c mice. Data are expressed as mean ± SD of three experiments. A) Haematoxylin and eosin-stained granulomatous response in BALB/c mice after 4–7 days of piperlongumine (PL) treatment after TDM challenge. B) Inflammatory intensity level in lungs removed from TDM-challenged mice on days 4 and 7. P1 – PL at 50 mg/mL; P2 – PL at 100 mg/mL; P3 – PL at 150 mg/mL; DEX – dexamethasone; ns – non-significant, P > 0.05; * P < 0.05; ** P < 0.01; *** P <0.001 vs TDM-treated group
Diminution by piperlongumine of trehalose 6,6-dimycolate (TDM)-stimulated pulmonary granulomatous inflammation in BALB/c mice. Data are expressed as mean ± SD of three experiments. A) Haematoxylin and eosin-stained granulomatous response in BALB/c mice after 4–7 days of piperlongumine (PL) treatment after TDM challenge. B) Inflammatory intensity level in lungs removed from TDM-challenged mice on days 4 and 7. P1 – PL at 50 mg/mL; P2 – PL at 100 mg/mL; P3 – PL at 150 mg/mL; DEX – dexamethasone; ns – non-significant, P > 0.05; * P < 0.05; ** P < 0.01; *** P <0.001 vs TDM-treated group

Fig. 6

Effect of piperlongumine on trehalose 6,6-dimycolate (TDM)-stimulated pulmonary granulomatous inflammation in BALB/c mice. Data are expressed as mean ± SD of three experiments. Graphs show production of tumour necrosis factor alpha (TNF-α), interleukin 6 (IL-6), interleukin 10 (IL-10), keratinocyte-derived cytokine (KC), C-C motif chemokine ligand 5 (CCL-5), C-C motif chemokine ligand 10 (CXCL-10) and C-C motif chemokine ligand 2 (CCL-2) in pulmonary homogenates after 4 and 7 days of TDM stimulation with or without piperlongumine (PL) treatment. P1 – PL at 50 mg/mL; P2 – PL at 100 mg/mL; P3 – PL at 150 mg/mL; DEX – dexamethasone; ns – non-significant, P > 0.05; * P < 0.05; ** P < 0.01; *** P < 0.001 vs TDM-treated group
Effect of piperlongumine on trehalose 6,6-dimycolate (TDM)-stimulated pulmonary granulomatous inflammation in BALB/c mice. Data are expressed as mean ± SD of three experiments. Graphs show production of tumour necrosis factor alpha (TNF-α), interleukin 6 (IL-6), interleukin 10 (IL-10), keratinocyte-derived cytokine (KC), C-C motif chemokine ligand 5 (CCL-5), C-C motif chemokine ligand 10 (CXCL-10) and C-C motif chemokine ligand 2 (CCL-2) in pulmonary homogenates after 4 and 7 days of TDM stimulation with or without piperlongumine (PL) treatment. P1 – PL at 50 mg/mL; P2 – PL at 100 mg/mL; P3 – PL at 150 mg/mL; DEX – dexamethasone; ns – non-significant, P > 0.05; * P < 0.05; ** P < 0.01; *** P < 0.001 vs TDM-treated group

Fig. 7

Inhibition by piperlongumine (PL) of leukocyte infiltration in trehalose 6,6-dimycolate (TDM)-stimulated pulmonary granulomatous inflammation in BALB/c mice. Data are expressed as mean ± SD of three experiments. A) CD11b+ Ly6G−macrophages. B) CD11b+ lymphocyte antigen 6 complex locus G6D (Ly6G+)–neutrophils. C) chemokine receptor type 3 (CCR3)+ CD16/32−eosinophils. Bar charts represent quantitative measurement of positively stained cells. P1 – PL at 50 mg/mL; P2 – PL at 100 mg/mL; P3 –PL at 150 mg/mL; DEX – dexamethasone; ns – non-significant, P > 0.05; * P < 0.05; ** P < 0.01; *** P < 0.001 vs TDM-treated group
Inhibition by piperlongumine (PL) of leukocyte infiltration in trehalose 6,6-dimycolate (TDM)-stimulated pulmonary granulomatous inflammation in BALB/c mice. Data are expressed as mean ± SD of three experiments. A) CD11b+ Ly6G−macrophages. B) CD11b+ lymphocyte antigen 6 complex locus G6D (Ly6G+)–neutrophils. C) chemokine receptor type 3 (CCR3)+ CD16/32−eosinophils. Bar charts represent quantitative measurement of positively stained cells. P1 – PL at 50 mg/mL; P2 – PL at 100 mg/mL; P3 –PL at 150 mg/mL; DEX – dexamethasone; ns – non-significant, P > 0.05; * P < 0.05; ** P < 0.01; *** P < 0.001 vs TDM-treated group
Sprache:
Englisch
Zeitrahmen der Veröffentlichung:
4 Hefte pro Jahr
Fachgebiete der Zeitschrift:
Biologie, Molekularbiologie, Mikrobiologie und Virologie, Biologie, andere, Medizin, Veterinärmedizin
Zeitschrift RSS Feed